Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Achilles Therapeutics has raised $4.1M in total funding. The most recent round was Grant. The last funding was announced in July 2022.
Achilles Therapeutics's investors include RA Capital Management, Perceptive Advisors, OrbiMed, Redmile Group, Forbion Capital Partners.
Achilles Therapeutics is headquartered in London, United Kingdom.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Achilles Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Achilles Therapeutics — Funding & Investors." VCBacked, July 21, 2022, https://www.vcbacked.co/company/achilles-therapeutics. Accessed August 13, 2026.
VCBacked. (2022). Achilles Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/achilles-therapeutics
{{cite web |title=Achilles Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/achilles-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated